BI 54903 XX
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BI 54903 XX, covering 2014-08-20 to 2014-08-21. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers [Phase 1]